Yu U Chen

US Patent:

20210074160, Mar 11, 2021

Filed:

Feb 28, 2020

Appl. No.:

16/804967

Inventors:

- Dearborn MI, US
Jonathan Scott - Chelmsford, GB
John Lippe - Westcliff on Sea, GB
Giuseppe Calo - Stratford, GB
Daniel Gimeno Ferrer - Brentwood, GB
Yu Chen - Belleville MI, US
Arnold Babila - Ann Arbor MI, US
Junheung Park - Royal Oak MI, US

Assignee:

Ford Global Technologies, LLC - Dearborn MI

International Classification:

G08G 1/16
G07C 5/02
G08G 1/0962
G08G 1/01
G05D 1/02
B60W 60/00

Abstract:

A controller for a vehicle is configured to determine a driving behaviour of a first vehicle and a second vehicle. The controller is configured to receive data relating to at least one of a flow of traffic at the given location and a geography at the given location. If the controller determines that the driving behaviour of the first vehicle and the driving behaviour of the second vehicle are similar and the controller determines that at least one of the flow of traffic at the given location departs from a normal traffic flow and the geography at the given location increases the risk of accident, then the controller is configured to issue an alert.

US Patent:

20190099420, Apr 4, 2019

Filed:

Nov 5, 2018

Appl. No.:

16/181161

Inventors:

- Cleveland OH, US
Yu Chen - Cleveland OH, US
Akiko Maeda - Cleveland OH, US

International Classification:

A61K 31/4985
A61K 31/517
A61K 45/06
A61K 31/185
A61K 31/138
A61K 31/18
A61K 31/48

Abstract:

A method of treating an ocular disorder in a subject includes administering to the subject subtherapeutic amounts of two or more agents that inhibit and/or blocks the activation of Gs- or Gq-protein coupled receptors or Gs- or Gq-signaling cascade in ocular cells of the subject, and/or activates Gi-protein coupled receptors, which is induced or triggered by light induced all-trans-retinal generation.

US Patent:

20180258261, Sep 13, 2018

Filed:

Sep 22, 2016

Appl. No.:

15/761866

Inventors:

- Akron OH, US
Yu CHEN - Hudson OH, US

International Classification:

C08L 9/02
C09J 11/08
C09J 163/00

Abstract:

Novel method for production of epoxy terminated butadiene and butadiene acrylonitrile copolymer tougheners synthesized through the use of hydroxyl terminated polybutadiene and hydroxyl terminated butadiene acrylonitrile copolymers as starting materials. The epoxy terminated butadiene and butadiene acrylonitrile copolymers synthesized by the novel method have unexpectedly lower viscosity, contain no free epoxy and provide good improvements in T-peel resistance over traditional tougheners produced using traditional methods. Adhesives, composites and coatings utilizing the tougheners of the inventive method are within the scope of the invention.

US Patent:

20180071285, Mar 15, 2018

Filed:

Apr 14, 2017

Appl. No.:

15/487963

Inventors:

- Cleveland OH, US
Yu Chen - Cleveland OH, US

International Classification:

A61K 31/4985
A61K 31/138
A61K 31/185
A61K 31/517

Abstract:

A method of treating an ocular disorder in a subject includes administering to the subject subtherapeutic amounts of two or more agents that inhibit and/or blocks the activation of Gs- or Gq-protein coupled receptors or Gs- or Gq-signaling cascade in ocular cells of the subject, and/or activates Gi-protein coupled receptors, which is induced or triggered by light induced all-trans-retinal generation.

US Patent:

20140235562, Aug 21, 2014

Filed:

Apr 25, 2014

Appl. No.:

14/262141

Inventors:

- Cleveland OH, US
Yu Chen - Mayfield Heights OH, US

International Classification:

A61K 31/52
A61K 31/155
A61K 31/517
A61K 31/18
A61K 31/4178
A61K 31/505
A61K 31/495
A61K 31/454
A61K 31/475
A61K 31/4164
A61K 31/4453

US Classification:

514 46, 514401, 51426323, 5142634, 514561, 514632, 51425217, 514603, 514331, 514272, 51425503, 514567, 514558, 514564, 514560, 514559

Abstract:

A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).